Bellicum announced on 4/20/18 the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the... read more
Bellicum announced on 4/20/18 the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the... read more
Chemoimmunotherapy is a promising technology in the fight against cancer. Researchers at the University of Michigan Rogel Cancer Center have designed a new delivery system – a drug hidden in a... read more
Helsinn Group announced on 4/20/18 that the U.S. Food and Drug Administration (FDA) has approved the intravenous formulation of Akynzeo (NEPA, a fixed antiemetic combination of fosnetupitant,... read more
Vaxart announced on 4/20/18 that it received notification from Daiichi Sankyo Co., Ltd, that sales of Inavir, a single inhaled dose product licensed in Japan to prevent or treat influenza... read more
Veloxis Pharmaceuticals A/S announced on 4/19/18 that the U.S. Food & Drug Administration (FDA) has accepted for standard review the Company’s supplemental New Drug Application (sNDA) which... read more
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) on 4/19/18 announced the pricing of its previously announced underwritten public offering of 16,000,000 shares of its common stock, offered at a price of... read more
The Procter & Gamble Company (NYSE:PG) On 4/19/18 announced it has signed an agreement to acquire the Consumer Health business of Merck KGaA, Darmstadt, Germany, for a purchase price of... read more
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) On 4/19/18 announced positive data from EASE LID 2, the company’s two-year Phase 3 open-label study of GOCOVRI™ (amantadine) extended release... read more
Teva has announced that Teva and the Procter & Gamble Company [NYSE: PG] have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC (... read more
OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase I/... read more
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that the U.S. Food and Drug... read more
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has been granted Orphan Drug Designation by the United States FDA... read more
Solid Biosciences announced today that they are working with the FDA to resolve questions related the to clinical hold placed on the IGNITE DMD trial in Duchenne muscular dystrophy patients.... read more
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the U.S. Food and Drug Administration (FDA) approved Tavalisse (fostamatinib disodium hexahydrate) for the treatment of... read more
Catabasis Pharmaceuticals today announced a restructuring of the organization to focus resources on the Company’s late-stage lead program, edasalonexent for the treatment of Duchenne muscular... read more
Elios Therapeutics, a biopharmaceutical company developing particle-delivered, dendritic cell vaccines in the oncology arena, today presented initial open-label results from the ongoing Phase 2b ... read more
The drive to bring more transparency to healthcare costs can be seen at both the federal and state levels (see some... read more
Torque, an immuno-oncology company developing Deep Primed cellular therapies with pharmacologic control to direct immune power deep within the tumor microenvironment, announced today preclinical... read more
